Page 113 - 《中国药房》2023年3期

参考文献 [14] OKURA F，SATO Y，MURAKAMI E，et al. A case of in‐
[ 1 ] U. S. Food and Drug Administration. Palbocilib（IBRANCE） terstitial pneumonitis induced by palbociclib[J]. Gan To
[EB/OL]. [2022-11-10]. https：//www.fda.gov/drugs/re- Kagaku Ryoho，2020，47（6）：997-999.
sources-informationapproved-drugs/palbociclib-ibrance. [15] MATHEW N，JOEL A，ANDREWS A G，et al. CDK4/6
[ 2 ] U. S. Food and Drug Administration.Ribocilib（Kisqali） inhibitor induced lung injury：a case report and review of
[EB/OL]. [2022-11-10]. https：//www. fda. gov/drugs/ literature[J]. Ecancermedicalscience，2021，15：1245.
resources-informationapproved-drugs/ribociclib-kisqali. [16] LEVY OFER M D，PTASHKIN EKATERINA M D，
[ 3 ] U. S. Food and Drug Administration. FDA aprroves abe‐ SHECHTMAN YITZHAK M D，et al. Fatal palbociclib-
maciclib for HR-positive，HER2-negative breast cancer related interstitial pneumonitis[J]. Arch Clin Med Case
[EB/OL]. [2022-11-10]. https：//www. fda. gov/drugs/ Rep，2019，3（4）：162-166.
resources-information-approved-drugs/fdaapproves- [17] ALGWAIZ G，BADRAN A A，ELSHENAWY M A，et al.
abemaciclib-hr-positive-her2-negative-breast-cancer. Ribociclib-induced pneumonitis：a case report[J]. Breast
[ 4 ] QIN Q，LI X Q，LIANG X M，et al. CDK4/6 inhibitor pal‐ Care （Basel），2021，16（3）：307-311.
bociclib overcomes acquired resistance to third-generation [18] RAJENDRAN A，KUNOOR A，PUSHPA RAGAHAVAN
EGFR inhibitor osimertinib in non-small cell lung cancer R，et al. Ribociclib-associated organising pneumonia[J].
（NSCLC）[J]. Thorac Cancer，2020，11（9）：2389-2397. BMJ Case Rep，2021，14（12）：e245187.
[ 5 ] JO H，PARK Y，KIM T，et al. Modulation of SIRT3 ex‐ [19] SADOWSKA A M，SPECENIER P，GERMONPRE P，
pression through CDK4/6 enhances the anti-cancer effect et al. Antineoplastic therapy-induced pulmonary toxicity
of sorafenib in hepatocellular carcinoma cells[J]. BMC [J]. Expert Rev Anticancer Ther，2013，13（8）：997-1006.
Cancer，2020，20（1）：332. [20] RASCHI E，FUSAROLI M，ARDIZZONI A，et al. Cyclin-
[ 6 ] AHSAN I，MALIK F，JAFRI S. Palbociclib related dependent kinase 4/6 inhibitors and interstitial lung
pnemotoxicity：a rare side effect[J]. Am J Respir Crit Care disease in the FDA adverse event reporting system：a phar‐
Med，2017，195：A5546. macovigilance assessment[J]. Breast Cancer Res Treat，
[ 7 ] KOMODA A，KASHIWAGI S，KAWANO Y，et al. A case 2021，186（1）：219-227.
of liver abscess during treatment for abemaciclib-induced [21] LEE M Y，YOON S Y，KIM K H，et al. Pulmonary toxici‐
interstitial lung disease[J]. Gan To Kagaku Ryoho，2022， ties of molecular targeted antineoplastic agents：a single-
49（1）：100-102. center 10-year experience[J]. Korean J Intern Med，2021，
[ 8 ] MITARAI Y，TSUBATA Y，HYAKUDOMI M，et al. 36（3）：689-698.
Drug-induced eosinophilic pneumonia as an adverse event [22] 日本乳癌学会 . 乳癌診療ガイドライン2018 年版[EB/
of abemaciclib[J]. Cureus，2022，14（1）：e21741. OL]. [2021-11-18]. https：//jbcs. xsrv. jp/guidline/2018/in‐
[ 9 ] JAZIEH K A，BUDD G T，DALPIAZ N，et al. Can CDK4/6 dex/yakubutu/y2-cq-15/.
inhibitors cause fatal lung injury?[J]. Expert Rev Anticancer [23] FLAHERTY K T，LORUSSO P M，DEMICHELE A，
Ther，2019，19（11）：917-919. et al. Phase Ⅰ ，dose-escalation trial of the oral cyclin-
[10] FELIP E，LLOBERA L，PEREZ-MAÑÁ C，et al. New dependent kinase 4/6 inhibitor PD 0332991，administered
drugs，old toxicities：pneumonitis related to palbociclib： using a 21-day schedule in patients with advanced cancer
a case report[J]. Breast Care （Basel），2020，15（5）： [J]. Clin Cancer Res，2012，18（2）：568-576.
548-552. [24] SANDBERG L，TAAVOLA H，AOKI Y，et al. Risk factor
[11] STOFFAËS L，DUMAZET A，DESLEE G，et al. considerations in statistical signal detection：using sub‐
Sarcoidosis-like reaction during palbociclib treatment for group disproportionality to uncover risk groups for ad‐
metastatic breast cancer：a case report[J]. Breast J，2020， verse drug reactions in VigiBase[J]. Drug Saf，2020，43
26（6）：1239-1241. （10）：999-1009.
[12] DAVID S，HO G，DAY D，et al. Enhanced toxicity with [25] KAUFMAN G. Adverse drug reactions：classification，sus‐
CDK4/6 inhibitors and palliative radiotherapy：non-con- ceptibility and reporting[J]. Nurs Stand，2016，30（50）：
secutive case series and review of the literature[J]. Transl 53-63.
Oncol，2021，14（1）：100939. [26] CONTE P，ASCIERTO P A，PATELLI G，et al. Drug-
[13] GONG J，CHO M，YU K W，et al. A single institution ex‐ induced interstitial lung disease during cancer therapies：
perience with palbociclib toxicity requiring dose modifica‐ expert opinion on diagnosis and treatment[J]. ESMO
tions[J]. Breast Cancer Res Treat，2018，168（2）：381-387. Open，2022，7（2）：100404.

中国药房 2023年第34卷第3期 China Pharmacy 2023 Vol. 34 No. 3 · 359 ·